Clinical Trial Detail

NCT ID NCT02197247
Title Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Osimertinib + Rifampin

Osimertinib

Age Groups: senior adult

No variant requirements are available.